Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov;74(11):1459-62.
doi: 10.1016/j.humimm.2013.06.006. Epub 2013 Jun 15.

Role of anti-vimentin antibodies in allograft rejection

Marlene L Rose  1
Affiliations
Review

Role of anti-vimentin antibodies in allograft rejection

Marlene L Rose. Hum Immunol. 2013 Nov.

Abstract

Production of anti-vimentin antibodies (AVA) after solid organ transplantation are common. Although classically thought to be expressed mainly within the cytosol, recent evidence demonstrates that extracellular or cell surface expression of vimentin is not unusual. This review examines the evidence to assess whether AVA contribute to allograft pathology. Clinical studies suggest that AVA are associated with cardiac allograft vasculopathy in heart transplant recipients. Studies in non-human primates confirm that production of AVA after renal and heart transplantation are not inhibited by Cyclosporine. Experimental studies have demonstrated that mice pre-immunised with vimentin undergo accelerated acute rejection and vascular intimal occlusion of cardiac allografts. Adoptive transfer of hyperimmune sera containing AVA into B-cell-knock-out mice caused accelerated rejection of allografted hearts, this is clear evidence that antibodies to vimentin accelerate rejection. AVA act in concert with the alloimmune response and AVA do not damage syngeneic or native heart allografts. Confocal microscopy of allografted organs in vimentin immunised mice shows extensive expression of vimentin on endothelial cells, apoptotic leukocytes and platelet/leukocyte conjugates, co-localising with C4d. One explanation for the ability of AVA to accelerate rejection would be fixation of complement within the graft and subsequent pro-inflammatory effects; there may also be interactions with platelets within the vasculature.

Keywords: AMR; AVA; CFA; HMEC; MMF; PAF; anti-vimentin antibodies; antibody mediated rejection; complete Freund’s adjuvant; human microvascular endothelial cells; mycophenolate mofetil; platelet activating factor.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Thebault S., Gilbert D., Hubert M., Drouot L., Machour N., Lange C. Orderly pattern of development of the autoantibody response in (New Zealand White x BXSB) F1 lupus mice: characterization of target antigens and antigen spreading by two-dimensional gel electrophoresis and mass spectrometry. J Immunol. 2002;169:4046–4053. - PubMed
    1. Vossenaar E.R., Despres N., Lapointe E., Van der H.A., Lora M., Senshu T. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther. 2004;6:R142–R150. - PMC - PubMed
    1. Azimzadeh A.M., Pfeiffer S., Wu G.S., Schroder C., Zhou H., Zorn G.L., III Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates. Am J Transplant. 2005;5:2349–2359. - PubMed
    1. Jonker M., Danskine A., Haanstra K., Wubben J., Kondova I., Kuhn E.M. The autoimmune response to vimentin after renal transplantation in nonhuman primates is immunosuppression dependent. Transplantation. 2005;80:385–393. - PubMed
    1. Jurcevic S., Ainsworth M.E., Pomerance A., Smith J.D., Robinson D.R., Dunn M.J. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation. 2001;71:886–892. - PubMed

Publication types